- Home
- STRW vs ACTU Comparison
STRW vs ACTU Comparison
Compare STRW & ACTU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STRW
- ACTU
- Stock Information
- Founded
- STRW 2015
- ACTU 2015
- Country
- STRW United States
- ACTU United States
- Employees
- STRW N/A
- ACTU N/A
- Industry
- STRW Real Estate Investment Trusts
- ACTU
- Sector
- STRW Real Estate
- ACTU
- Exchange
- STRW Nasdaq
- ACTU NYSE
- Market Cap
- STRW 119.6M
- ACTU 135.0M
- IPO Year
- STRW N/A
- ACTU 2024
- Fundamental
- Price
- STRW $10.97
- ACTU $8.00
- Analyst Decision
- STRW Strong Buy
- ACTU Strong Buy
- Analyst Count
- STRW 4
- ACTU 1
- Target Price
- STRW $13.83
- ACTU $20.00
- AVG Volume (30 Days)
- STRW 126.7K
- ACTU 42.0K
- Earning Date
- STRW 05-13-2025
- ACTU 05-21-2025
- Dividend Yield
- STRW 5.15%
- ACTU N/A
- EPS Growth
- STRW 46.58
- ACTU N/A
- EPS
- STRW 0.57
- ACTU N/A
- Revenue
- STRW $117,058,000.00
- ACTU N/A
- Revenue This Year
- STRW $13.05
- ACTU N/A
- Revenue Next Year
- STRW $4.29
- ACTU N/A
- P/E Ratio
- STRW $19.08
- ACTU N/A
- Revenue Growth
- STRW 17.29
- ACTU N/A
- 52 Week Low
- STRW $8.19
- ACTU $5.51
- 52 Week High
- STRW $12.90
- ACTU $11.73
- Technical
- Relative Strength Index (RSI)
- STRW 46.61
- ACTU N/A
- Support Level
- STRW $10.15
- ACTU N/A
- Resistance Level
- STRW $11.25
- ACTU N/A
- Average True Range (ATR)
- STRW 0.90
- ACTU 0.00
- MACD
- STRW -0.04
- ACTU 0.00
- Stochastic Oscillator
- STRW 66.57
- ACTU 0.00
About STRW Strawberry Fields REIT Inc.
Strawberry Fields REIT Inc is a self-managed and self-administered company that specializes in the acquisition, ownership and triple-net leasing of skilled nursing facilities and other post-acute healthcare properties.
About ACTU ACTUATE THERAPEUTICS INC
Actuate Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). It is developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3B, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, that lead to tumor cell survival, growth, migration, and invasion.